In head-to-head trial of oral GLP-1s, orforglipron superior to semaglutide

Key takeaways:

Orforglipron, a novel oral GLP-1, was superior to oral semaglutide for lowering HbA1c and weight in patients with type 2 diabetes.

Regulatory approval for orforglipron will be sought in 2026.

In a trial comparing two oral GLP-1s, orforglipron was superior to semaglutide for glycemic control and weight loss in patients with type 2 diabetes, according to topline results announced by Eli Lilly.

For the ACHIEVE-3 trial, researchers randomly assigned 1,698 adults with type 2 diabetes inadequately controlled with metformin (mean HbA1c at baseline, 8.3%) to orforglipron (Eli Lilly) 12 mg, orforglipron 36 mg, oral semaglutide (Rybelsus, Novo Nordisk) 7 mg or oral semaglutide 14 mg, according to a press release from Eli Lilly.

Orforglipron conferred greater HbA1c and body we